Dr. Matthew Galsky interprets latest atezolizumab/chemo results in bladder cancer
Matthew D. Galsky, MD, interprets the results from the final overall survival (OS) analysis of the IMvigor130 trial, which were shared during the 2021 American Association for Cancer Research Virtual Annual Meeting. The IMvigor130 trial randomized patients with metastatic urothelial carcinoma to atezolizumab plus platinum/gemcitabine; atezolizumab alone; or placebo plus platinum/gemcitabine.
Galsky says that the final OS analysis comparing atezolizumab/chemo versus placebo/chemo did not show a statistically significant OS benefit with atezolizumab, and thus, OS follow-up remains ongoing. Galsky also discusses the finding from an exploratory analysis which suggest that outcomes with atezolizumab/chemo might be affected by the specific platinum regimen used.
Galsky is professor of Medicine; director of Genitourinary Medical Oncology; director of the Novel Therapeutics Unit; and co-director of the Center of Excellence for Bladder Cancer at the Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai.
Advancing bladder cancer care: The importance of integrating mental health support
September 9th 2024"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
